Services >> Preclinical >> Anti-infectives

In vivo / preclinical – anti-infectives

Sidebar Image

In vivo services to find the next generation drugs that combat infectious disease

With the rising prevalence of drug-resistant microorganisms, effective and potent anti-infective agents are becoming increasingly more relevant in order to treat infectious diseases. Eurofins, through the expertise of Panlabs, identified this need over 25 years ago and has since been working diligently with the pharmaceutical industry to provide a robust portfolio of in vitro and in vivo anti-infective models to support the discovery and development of novel antimicrobial therapies.

Eurofins is dedicated to taking your anti-infective program from in vitro screens to preclinical testing.  Our broad panel contains over 40 validated assays used to evaluate the efficacy of your drug candidates in infection models. Our validated methods are optimized for minimal data scatter and are demonstrated dose-responsive to standard antimicrobial agents. The models have been used to test small molecules, drug combinations, biologics, RNAi, liposomal formulations, nanoparticles, and vaccines.

Features of in vivo anti-infective services from Eurofins:

  • Over 40 validated assays in infection models
    • Infection types include:
      • Colitis, C. difficile,
      • Excisional wound
      • Intra-abdominal, cecal puncture
      • Lung, ocular, peritonitis, septicemia, skin, thigh (deep tissue), and vaginal
    • Pathogen types include:
      • Anaerobic bacteria: C. difficile, P. vulgaris
      • Fungi: C. albicans, A. fumigatus
      • Gram-negative bacteria: A. baumannii, E. coli, K. pneumoniae, N. gonorrhoeae, P. aeruginosa
      • Gram-positive bacteria: E. faecalis, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes
  • Fast turnaround of five weeks
  • Multiple readouts offered:
    • Microbial counts in tissue
    • Counts of resistant microbial variants
    • Histopathology
    • Host survival
    • PK exposure
    • Cytokine profile
  • Flexible  dosing methods to support all routes of administration
  • Ability to develop custom models upon request
  • Companion in vitro services for early anti-microbial assessment